Skip to main content
Equibles
NTLA logo

NTLA · Intellia Therapeutics, Inc. · Metrics

Track NTLA — free

Use NTLA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NTLA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.89 +0.31 (+2.68%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.62B
Shares
140.13M
Volume · Oct 20 3.41M Avg daily vol (3M) 4.33M

NTLA metrics

84 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.84
Market cap
$1.62B

Price action

20 metrics
Price change (1W)
-7.9%
Price change (30D)
-5.2%
Price change (3M)
+6.0%
Price change (6M)
-23.9%
Price change (YTD)
+28.8%
Price change (1Y)
-53.2%
Trailing year
Price change (5Y)
-91.3%
52-week high
$27.98
52-week low
$8.04
Change from 52-week high
-58.6%
Change from 52-week low
+44.0%
Annualized volatility
90.5%
Annualized volatility (3M)
58.7%
Beta
2.2
RSI (14D)
44.7
Price vs SMA 50
-5.5%
Price vs SMA 200
-11.0%
Avg volume (3M)
4.33M
Relative volume
0.8
Average dollar volume
$52.05M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
140.13M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
19.5×
reciprocal yield 5.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
26.9×
reciprocal yield 3.7%
P / book
2.2
reciprocal yield 45.5%
FCF yield
-21.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-25.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
22.5×
reciprocal yield 4.4%
EV / revenue historical average (5Y)
22.5×
reciprocal yield 4.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-711.7%
Trailing 12 months
Net margin
-672.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$423.48M
Net income (TTM)
−$399.98M
Trailing 12 months
Diluted EPS (TTM)
$-3.34
FCF margin
-586.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.51
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.56
EBITDA per diluted share (TTM)
$-3.48
Net income per diluted share (TTM)
$-3.36
Operating cash flow per diluted share (TTM)
$-2.91
Free cash flow per diluted share (TTM)
$-2.92
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$2.92
Stock compensation per diluted share (TTM)
$0.57
Book value per share
$5.77

Growth

11 metrics
Revenue growth YoY
-46.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$59.51M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+28.7%
Year over year · more shares
Revenue CAGR (3Y)
+9.1%
Revenue CAGR (5Y)
+3.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-55.0%
Return on assets
-46.7%
Debt / equity
0.0
Current ratio
6.6
EBITDA (TTM)
−$414.41M
Free cash flow (TTM)
−$348.69M
Quick ratio
6.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$437.76M
Latest balance sheet
Cash & equivalents
$106.13M
Total assets
$857.16M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$346.64M
Capital expenditures (TTM)
$2.04M
R&D (TTM)
$346.73M
SG&A (TTM)
—
Stock compensation (TTM)
$67.90M
R&D / revenue
582.7%
Stock compensation / revenue
114.1%

Ownership (13F)

9 metrics
13F filers
333
13F filer change QoQ
+22
Institutional ownership
105.7%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+34.2%
Holder tenure
14.9
Price vs estimated holder cost
+15.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
21.5%

Short interest

3 metrics
Short interest
32.2%
Latest settlement · 9.5 days to cover
Days to cover
9.5d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$401,237
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1652130 CUSIP 45826J105 13F (30d) 32 filings 28 filers Visit website Investor relations